Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cyclacel Pharmaceuticals Inc

CYCC
Current price
1.69 USD +0.04 USD (+2.42%)
Last closed 1.65 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 707 031 USD
Yield for 12 month +122.37 %
1Y
3Y
5Y
10Y
15Y
CYCC
21.11.2021 - 28.11.2021

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey. Address: 200 Connell Drive, Berkeley Heights, NJ, United States, 07922

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

11 USD

P/E ratio

Dividend Yield

Current Year

+420 000 USD

Last Year

+373 000 USD

Current Quarter

+29 000 USD

Last Quarter

+31 000 USD

Current Year

+389 000 USD

Last Year

-32 000 USD

Current Quarter

+27 000 USD

Last Quarter

+23 000 USD

Key Figures CYCC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -22 464 000 USD
Operating Margin TTM -15017.24 %
PE Ratio
Return On Assets TTM -99.6 %
PEG Ratio
Return On Equity TTM -496.02 %
Wall Street Target Price 11 USD
Revenue TTM 449 000 USD
Book Value -1.67 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM -455 000 USD
Earnings per share -22.02 USD
Diluted Eps TTM -22.02 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CYCC

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CYCC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:15
Payout Ratio
Last Split Date 18.12.2023
Dividend Date 15.04.2020

Stock Valuation CYCC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 6.0999
Price Sales TTM 5.5241
Enterprise Value EBITDA 0.0402
Price Book MRQ 3.8223

Financials CYCC

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CYCC

For 52 weeks

1.3 USD 13.2 USD
50 Day MA 2.08 USD
Shares Short Prior Month 145 316
200 Day MA 3.82 USD
Short Ratio 0.07
Shares Short 94 504
Short Percent 10.53 %

Dynamics of changes in the value of assets

Stocks


AAPL

AAPL

212.49 USD Apple Inc -1.32 (-0.62%)
Detailed analytics

ETF funds


S

SX7EEX

13.36 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) -0.53 (-3.54%)
Detailed analytics

Metals


Gold

2332.52 USD Gold +27.54 (+1.2%)
Detailed analytics